<code id='01B8F6EAFA'></code><style id='01B8F6EAFA'></style>
    • <acronym id='01B8F6EAFA'></acronym>
      <center id='01B8F6EAFA'><center id='01B8F6EAFA'><tfoot id='01B8F6EAFA'></tfoot></center><abbr id='01B8F6EAFA'><dir id='01B8F6EAFA'><tfoot id='01B8F6EAFA'></tfoot><noframes id='01B8F6EAFA'>

    • <optgroup id='01B8F6EAFA'><strike id='01B8F6EAFA'><sup id='01B8F6EAFA'></sup></strike><code id='01B8F6EAFA'></code></optgroup>
        1. <b id='01B8F6EAFA'><label id='01B8F6EAFA'><select id='01B8F6EAFA'><dt id='01B8F6EAFA'><span id='01B8F6EAFA'></span></dt></select></label></b><u id='01B8F6EAFA'></u>
          <i id='01B8F6EAFA'><strike id='01B8F6EAFA'><tt id='01B8F6EAFA'><pre id='01B8F6EAFA'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:fashion    Page View:74876
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In